XBI vs. ARKG
Compare and contrast key facts about SPDR S&P Biotech ETF (XBI) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
XBI and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. ARKG is an actively managed fund by ARK Investment Management. It was launched on Oct 31, 2014.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: XBI or ARKG.
Performance
XBI vs. ARKG - Performance Comparison
Returns By Period
In the year-to-date period, XBI achieves a 5.76% return, which is significantly higher than ARKG's -29.23% return. Over the past 10 years, XBI has outperformed ARKG with an annualized return of 4.95%, while ARKG has yielded a comparatively lower 2.20% annualized return.
XBI
5.76%
-4.04%
5.72%
29.73%
1.44%
4.95%
ARKG
-29.23%
-3.53%
-9.51%
-15.87%
-5.83%
2.20%
Key characteristics
| XBI | ARKG | |
|---|---|---|
| Sharpe Ratio | 1.18 | -0.36 |
| Sortino Ratio | 1.73 | -0.27 |
| Omega Ratio | 1.21 | 0.97 |
| Calmar Ratio | 0.54 | -0.18 |
| Martin Ratio | 3.96 | -0.64 |
| Ulcer Index | 7.86% | 22.65% |
| Daily Std Dev | 26.34% | 40.16% |
| Max Drawdown | -63.89% | -80.10% |
| Current Drawdown | -45.70% | -79.22% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XBI vs. ARKG - Expense Ratio Comparison
XBI has a 0.35% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Correlation
The correlation between XBI and ARKG is 0.83, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Risk-Adjusted Performance
XBI vs. ARKG - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
XBI vs. ARKG - Dividend Comparison
XBI's dividend yield for the trailing twelve months is around 0.15%, while ARKG has not paid dividends to shareholders.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% | 0.17% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 1.94% | 1.34% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
XBI vs. ARKG - Drawdown Comparison
The maximum XBI drawdown since its inception was -63.89%, smaller than the maximum ARKG drawdown of -80.10%. Use the drawdown chart below to compare losses from any high point for XBI and ARKG. For additional features, visit the drawdowns tool.
Volatility
XBI vs. ARKG - Volatility Comparison
The current volatility for SPDR S&P Biotech ETF (XBI) is 8.40%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 13.74%. This indicates that XBI experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.